HLA-A*0101 MAGE-A3 Complex Protein, Human (Biotinylated, EVDPIGHLY, HEK293, His-Avi)

HLA-A*0201 MAGE-A3 Complex Protein, a vital member of the major histocompatibility complex (MHC) class I family, facilitates immune recognition and response to hepatitis B virus (HBV). By presenting HBV-derived peptides to cytotoxic T cells, it contributes to antiviral defense mechanisms within the MHC class I pathway, emphasizing its pivotal role in adaptive immunity and immune system surveillance against infected or aberrant cells. HLA-A*0101 MAGE-A3 Complex Protein, Human (Biotinylated, EVDPIGHLY, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*0101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and EVDPIGHLY peptide. HLA-A*0101 MAGE-A3 Complex Protein, Human (Biotinylated, EVDPIGHLY, HEK293, His-Avi), has molecular weight of 53-63 kDa.

The HLA-A*0201 HBV Complex Tetramer Protein is a member of the major histocompatibility complex (MHC) class I family, integral to the immune system's ability to recognize and respond to foreign antigens. As part of this family, the protein is involved in presenting viral peptides derived from hepatitis B virus (HBV) to cytotoxic T cells, contributing to the immune response against HBV infection. The MHC class I pathway, in which this protein participates, plays a crucial role in the surveillance and elimination of infected or aberrant cells by the immune system. The specific interaction of HLA-A*0201 with HBV-derived peptides underscores its significance in adaptive immunity, highlighting its role in antiviral defense mechanisms.

Human

HEK293

C-Avi;C-His

Q5SUL5 (G25-T305)&P61769 (I21-M119)&EVDPIGHLY

3105&567

53-63 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.